Study on Pharmacodynamic Substances and Quality Control of Jiuwei Jiangtang Oral Liquid Based on Network Pharmacology, Fingerprint and In Vitro Experiment

Objective: This study aims to explore the fingerprint and quality control index components of Jiuwei Jiangtang Oral Liquid (JWJT), known for its therapeutic effects on type 2 diabetes mellitus (T2DM). Methods: This study employed network pharmacology and molecular docking to screen the core components, core targets, and pathways of JWJT. Additionally, HPLC fingerprint was established for 12 batches of JWJT. 12 batches of JWJT were evaluated using stoichiometry and common peaks were determined following a similarity assessment. The effective substances were selected to verify the index components of JWJT through assessing their control over glucose consumption in insulin-resistant HepG2 cells and their α-glucosidase inhibitory activity. Results: Through network pharmacology and molecular docking analysis, puerarin, calycosin, ellagic acid, kaempferol-3-O-rutinoside, and kaempferol were identified as core components of JWJT for treating T2DM. Key targets such as AKT1, PIK3R1, INSR, TNF, and EGFR were implicated in regulating pathways including HIF-1, MAPK, and PI3K-Akt in T2DM treatment. The HPLC fingerprints of 12 batches of JWJT samples revealed 10 common peaks, with puerarin, calycosin, ellagic acid, and kaempferol-3-O-rutinoside specifically identified among 4 chromatographic peaks. Using chemical pattern recognition, samples were categorized into two groups, with puerarin, calycosin, and ellagic acid identified as differential markers. Verification through glucose consumption in insulin-resistant HepG2 cells and α-glucosidase inhibitory activity confirmed that puerarin, calycosin, and ellagic acid were active ingredients suitable as quality control indicators for JWJT. Conclusion: The JWJT fingerprint method established in this study is both simple and reproducible. The selected index components will serve as the basis for quality control of JWJT and introduce a novel approach for selecting and verifying quality index components of JWJT in T2DM treatment.